Recent Posts
- 23andMe, a US-based biotech company, sees its stock plummet to new lows as Sequoia Capital reduces its stake.
- Innocan Pharma Discloses Financial Performance for Third Quarter 2024
- Lupin Announces FDA Approval of New Edema Treatment in the US Market
- Building bridges between our industry and policymakers
- Introducing Debut’s Game-Changing Biotech Offerings in Professional Beauty Routines